Summary of findings 2.
Diazepam compared with placebo for acute stroke
| Diazepam compared with placebo for acute stroke | ||||||
|
Patient or population: people with acute stroke Settings: inpatients Intervention: diazepam Comparison: placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Placebo | Diazepam | |||||
| Death or dependency | 513 per 1000 | 481 per 1000 | RR 0.94 (0.82 to 1.07) | 849 (1) | ⊕⊕⊕⊝ Moderate1 | — |
| Adverse events | 357 per 1000 | 355 per 1000 | RR 0.99 (0.75 to 1.31) | 865 (1) | ⊕⊕⊕⊝ Moderate1 | — |
| Functional independence | 487 per 1000 | 519 per 1000 | RR 1.07 (0.93 to 1.22) | 849 (1) | ⊕⊕⊕⊝ Moderate1 | — |
| Other stroke scales | Not reported | Not reported | — | — | — | — |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk Ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1Downgraded one level: one study with small sample size
Functional independence, defined as a BI score higher than 60 or a mRS score less than 3